Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients

Inclusion Criteria: 1. Pathologically confirmed invasive breast cancer (regardless of pathology type); 2. Female patients 18-40 years of age with unlimited HR, or 41-45 years of age with negative HR; 3. Patients expected to receive ≥4 cycles of chemotherapy containing paclitaxel or anthracycline-containing chemotherapeutic agents and ovarian protective drugs; 4. Pre-menopausal (including perimenopausal); 5. Good compliance, normal comprehension and ability to receive treatment as required; 6. ECOG score 0-1; 7. Patients volunteered to participate in this study and signed an informed consent form. Exclusion Criteria: 1. Use of any other vaginal medication in the 3 months prior to the study; 2. Use of any anti-infective medication in the 3 months prior to the study; 3. Active genital tract infection; 4. Previous development of other malignancies; 5. Any reason why they are unable to complete the full course of follow-up treatment as prescribed by their doctors; 6. AST and ALT ≥ 1.5 times the upper limit of normal, alkaline phosphatase ≥ 2.5 times the upper limit of normal, total bilirubin ≥ 1.5 times the upper limit of normal, serum creatinine ≥ 1.5 times the upper limit of normal; LVEF \< 50% on cardiac ultrasound; 7. Severe coagulation disorder, severe systemic disease, or uncontrollable infection; 8. Persons without personal freedom and independent civil capacity; the presence of mental disorders, addictions, etc., which in the judgment of the investigator do not qualify for enrolment.